ArticleNanotechnology, science and applications2025
Paclitaxel-Loaded Polyelectrolyte Nanocarriers: Uptake Mechanisms, Cytotoxicity, and Genotoxicity in Human Endothelial and Breast Cancer Cells.
Article in Nanotechnology, science and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polymeric Therapeutic Nanosystems Containing Paclitaxel: Novel Strategies, Therapeutic Potential, Challenges, and Translation Problems.Materials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study explores the therapeutic potential of sodium dodecyl sulphate (SDS)-based nanocarriers (NCs) for the targeted delivery of paclitaxel (PTX) to breast cancer (BC) cells, with a particular focus on the mechanisms governing their intracellular transport and biological activity. Methods: Two types of SDS-based NCs differing in polyelectrolyte composition: poly-L-lysine (SDS/PLL) and poly-L-lysine with poly-L-glutamic acid (SDS/PLL/PGA), were prepared following the Layer-by-Layer (LbL) technique. Cellular uptake and distribution of Rhodamine B (RhoB)-labelled NCs were assessed via fluorescence microscopy and quantified by flow cytometry across three human cell lines: dermal microvascular endothelial cell line (HMEC-1), epithelial breast adenocarcinoma cell line (MCF-7), and triple-negative, mesenchymal-like BC cell line (MDA-MB-231). The cytotoxic and genotoxic effects of PTX-loaded NCs were evaluated using spectrophotometric and spectrofluorimetric assays. In parallel, DNA damage-responsive gene expression was examined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Results: Both NC formulations demonstrated comparable uptake efficiency, despite differences in fluorescence intensity. Inhibitor-based studies revealed distinct internalization pathways: SDS/PLL NCs entered via dynamin-dependent endocytosis and macropinocytosis, whereas SDS/PLL/PGA NCs relied predominantly on macropinocytosis. Genotoxicity of PTX-loaded NCs was confirmed by comet assay and H2A histone family member X (γH2AX) phosphorylation, particularly in MCF-7 and MDA-MB-231 cells. Cell cycle perturbations and transcriptional changes in ataxia-telangiectasia mutated ( Conclusion: These findings delineate the cellular uptake mechanisms and in vitro biological effects of the examined polyelectrolyte NCs for PTX delivery, with a particular focus on their genotoxicity. Collectively, these in vitro data provide a mechanistic basis to inform the rational design and preclinical optimization of SDS-based NCs, supporting subsequent in vivo evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.